AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03685188
Drug: Sufentanil Citrate
RxNorm normalized name: Sufentanil Citrate
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive patient' controlled intravenous analgesia in analgesic pump with 2 μg/ml of sufentanil for postoperative analgesia.
Trial: NCT00630435
Drug: Premarin®/MPA formulation A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00630435
Drug: Premarin®/MPA formulation B
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00630435
Drug: Premarin®/MPA formulation C
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00630435
Drug: Premarin®/MPA currently marketed product
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00163020
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly doses of placebo (NS + preservatives) via injection as early as 19weeks until 34.0weeks gestation or delivery which ever comes first.
Trial: NCT00125320
Drug: RSD1235
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02683824
Drug: [18F]FP-R01-MG-F2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: radioactive tracer
Trial: NCT03804411
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of:~1. B -vildagliptin 100 mg/day~2. B - sitagliptin 100 mg/day,~3. B- dapagliflozin 10 mg/day~4. B- empagliflozin 10 mg/day~5. B- liraglutide 1,2-1,8 mg/day~6. B- exenatide 20 μg/day~7. B - glimepiride~8. B - gliclazide
Trial: NCT01370265
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes.
Trial: NCT03343626
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline (0.9% NaCl) IM injection.
Trial: NCT01779882
Drug: Busulfan-Cyclophosphamide as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation
RxNorm normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
Trial: NCT01779882
Drug: Cyclophosphamide-Busulfan as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation
RxNorm normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
Trial: NCT00615017
Drug: AZD9773 (CytoFab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusions
Trial: NCT00673335
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00602420
Drug: naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral naproxen twice daily for 5-8 days.
Trial: NCT01317225
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg intramuscular (gluteal muscles)biweekly from enrollment until delivery.
Trial: NCT02501629
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered by qualified study personnel as subcutaneous injections in the upper arm(s) once every 4 weeks for a total of 6 doses. Drug was supplied in pre-filled syringes.
Trial: NCT02501629
Drug: Non-Oral Corticosteroid (non-OCS) Asthma Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants continue using their non-OCS background asthma medications without change during the study's treatment period.
Trial: NCT02501629
Drug: Oral Corticosteroid (OCS)
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After screening and prior to study start, the participant's OCS dose was adjusted to determine the minimal effective OCS requirement.
Trial: NCT01268891
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily; tablet; orally; 18 weeks
Trial: NCT01268891
Drug: Azilect®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg daily; tablet; orally; 18 weeks
Trial: NCT00657982
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg BID
Trial: NCT02185066
Drug: CJ-30056 20/500mg (Test)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 receives Atorvastatin 20mg and Metformin XR 500mg first, then CJ-30056 second, with at 7-day wash-out period in between.~Group 2 receives CJ-30056 first, then Atorvastatin 20mg and Metformin XR 500mg second, with 7-day wash-out period in between.
Trial: NCT01748838
Drug: CTX-4430
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending single oral doses of CTX-4430 will be administered to subjects in 6 cohorts on day 1. Following a 14-day washout, subjects in two of the six cohorts will cross-over, fed a high fat diet and administered different single oral doses of CTX-4430
Trial: NCT01748838
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral doses of placebo will be administered to subjects in 6 cohorts on day 1. Following a 14-day washout, subjects in two of the six cohorts will cross over, fed a high fat diet and administered single oral doses of placebo
Trial: NCT01748838
Drug: CTX-4430
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending repeat doses of CTX-4430 will be administered orally, once-daily, to subjects in 4 cohorts on days 1-14.
Trial: NCT01748838
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat doses of placebo will be administered orally, once-daily, to subjects in 4 cohorts on days 1-14.
Trial: NCT04062591
Drug: Piroxicam group
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive 0.4 mg/kg piroxicam IM
Trial: NCT04062591
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline IM in the same dose of piroxicam
Trial: NCT04005599
Drug: Remifentanil group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venous general anesthesia with propofol and remifentanil.
Trial: NCT01416948
Drug: Placebo Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients randomly assigned to the placebo arm of the study, placebo will be administered BID at Week 0 through Week 12. Matching placebo will be administered to match the taper period.
Trial: NCT02210702
Drug: Ethinyl Estradiol 35mcg/Norethindrone 1mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02210702
Drug: Ethinyl Estradiol 20mcg/Norethindrone 1mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01480232
Drug: EVP-6124
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)
Trial: NCT01480232
Drug: Placebo Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo capsule ingested orally daily for 12 weeks (84 days)
Trial: NCT01480232
Drug: NicoDerm Patch (Active)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One NicoDerm patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).
Trial: NCT01480232
Drug: NRT Patch (Placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One NRT patch (Placebo) daily for first 6 weeks (42 days).
Trial: NCT01843205
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The pharmacodynamic effects of placebo methamphetamine will be determined during placebo and buspirone maintenance.
Trial: NCT02264015
Drug: Cilobradine, low, film-coated tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02264015
Drug: Cilobradine, high, film-coated tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02264015
Drug: Placebo, film-coated tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02661035
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/kg IV over 2 hours, day -6
Trial: NCT01917552
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine 1250 milligram (mg) / m² po bid (D1-14)
Trial: NCT03557385
Drug: adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FFR measurement with drug: adenosine. Intravenous adenosine will be administered at a rate of 140 μg/kg of body weight per minute x 2 minutes
Trial: NCT00857480
Drug: NRL972
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment and co-treatment with 1 g Cloxacillin t.i.d. for three days from the morning of D-3 until the morning of Day D01 0:30 hour before the intravenous administration of NRL972.
Trial: NCT03405974
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00857480
Drug: NRL972
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three week pre-treatment with daily doses of 500 mg b.i.d ursodeoxycholic acid from the morning of D-20 until the evening of Day D-1
Trial: NCT03613129
Drug: CT38
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Infusion
Trial: NCT04278820
Drug: TQA3526
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet(s) administered orally once daily
Trial: NCT04278820
Drug: Placebo to match TQA3526
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet(s) administered orally once daily
Trial: NCT02218190
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00837239
Drug: HuaChanSu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL/m2 for total 500 mL given as a 2 hour infusion, 5 days a week for 3 weeks then one week off (28 Day Cycle).
Trial: NCT00837239
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml saline only administered as a 2 hour infusion by central line.
Trial: NCT00468611
Drug: MBP8298
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg MBP8298 IV every six months for a period of two years
Trial: NCT02404064
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No perioperative antibiotics
Trial: NCT03107611
Drug: Placebo Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02414230
Drug: Drug: F 18 T807
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
Trial: NCT01803646
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel for intratympanic injection
Trial: NCT00675688
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01354717
Drug: Brand Carac
RxNorm normalized name: Carace
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment of actinic keratosis
Trial: NCT01354717
Drug: Generic 0.5% 5-fluorouracil cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment of actinic keratosis
Trial: NCT01355497
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subject will receive matching placebo for the duration of the trial
Trial: NCT03127436
Drug: Acarovac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: House dust mite sensitized Patients receive increasing doses of subcutaneous immunotherapy with Acarovac. During the up-dosing phase, patients will receive 4 injections in 1-2 week intervals with increasing allergen amount up to the individual maximum tolerable dose. After reaching the individual maximum tolerable dose patients will receive one maintenance dose in a 4 - 8 week interval.
Trial: NCT00369278
Drug: Enteric-coated mycophenolate sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration
Trial: NCT00420342
Drug: Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SH K 00641 A -Active study medication encapsulated tablet
Trial: NCT04066478
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03295760
Drug: Q10 Coenzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00668850
Drug: Regular human insulin
RxNorm normalized name: insulin, regular, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular human insulin 30 minutes before meals + BID NPH insulin AM and PM as pre-randomization dose.
Trial: NCT02244619
Drug: Oral acetaminophen
RxNorm normalized name: acetaminophen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the Oral acetaminophen arm will receive 2 Tylenol 500mg capsules. In this study, one arm receives an oral form of active medication and one arm receives an IV form of active medication. To keep the subject and study personnel blinded, subjects receiving Oral acetaminophen will also receive 100ml of IV Normal Saline similar to the delivery method of the IV acetaminophen arm. The Normal Saline IV placebo will be given not as an intervention but rather as a method to maintain study integrity.
Trial: NCT02244619
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the IV acetaminophen arm will receive Ofirmev 1000mg in 100ml Normal Saline IV plus 2 placebo capsules. In this study, one arm receives an oral form of active medication and one arm receives an IV form of active medication. To keep the subject and study personnel blinded, subjects receiving IV acetaminophen will also receive 2 placebo capsules similar to the delivery method of the oral acetaminophen arm. The placebo capsules will be given not as an intervention but rather as a method to maintain study integrity.
Trial: NCT03335774
Drug: Hydrocortisone Acetate Suppository, 25 mg (Nivagen)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One (1) Hydrocortisone Acetate Suppository, 25 mg is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
Trial: NCT03335774
Drug: Placebo (Vehicle) Suppository (Nivagen)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One (1) Placebo (Vehicle) Suppository is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
Trial: NCT02434718
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration of 0.9% sodium chloride
Trial: NCT01250002
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will receive the same volume of saline infusion.
Trial: NCT03795701
Drug: Saxenda®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receiving escalating dose of Saxenda® for the first 4 weeks (0.6mg, 1.2mg, 1.8mg, 2.4 mg) and receiving full-dose (3.0 mg) for 12 weeks.
Trial: NCT01002443
Drug: Helicobacter pylori eradication
RxNorm normalized name: Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg or Rabeprazole 10 mg bid + clarithromycin 500 mg and amoxicillin 1,000 mg bid for 7 days
Trial: NCT01002443
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg or Rabeprazole 10 mg bid + two placebo (for antibiotics) for 7 days
Trial: NCT03531606
Drug: Mechnicov probiotics
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'
Trial: NCT03531606
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'
Trial: NCT01320709
Drug: Piroxicam ( BAYl1902)
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of 20 mg piroxicam (i.e., 1 piroxicam capsule + 3 placebo capsule)
Trial: NCT01320709
Drug: Piroxicam ( BAYl1902)
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of 40 mg piroxicam (i.e., 2 piroxicam capsules + 2 placebo capsule)
Trial: NCT01320709
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of placebo (i.e., 4 placebo capsules)
Trial: NCT01320709
Drug: Piroxicam ( BAYl1902)
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of 80 mg piroxicam (i.e., 4 piroxicam capsules)
Trial: NCT02601703
Drug: Protopic® ointment, 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apply thin layer of ointment to affected area
Trial: NCT00001575
Drug: Calcium-DTPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca-DTPA will be administered intravenously on Days 1-3 to clear the radioactive agent from the body
Trial: NCT00831792
Drug: TK1258
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules (100 mg/capsules) of TKI 258 by mouth once daily (total of 400 mg of TKI258 per day).
Trial: NCT02605434
Drug: Accordion Pill™ Carbidopa/Levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AP-CD/LD capsule containing 50 mg carbidopa with 400 mg or 500 mg levodopa administered orally twice or 3 times a day
Trial: NCT02605434
Drug: Sinemet®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinemet® tables containing carbidopa and levodopa 25/100 mg will be administered orally at least 4 times a day according to patients need
Trial: NCT02605434
Drug: Placebo -AP-CD/LD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for AP-CD/LD capsule
Trial: NCT02605434
Drug: Placebo- Sinemet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Sinemet tables
Trial: NCT01199497
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).
Trial: NCT01199497
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00125957
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00550992
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00550992
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00550992
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00550992
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00550992
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00550992
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00588965
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given 1 pill daily for a week, then 2 pills daily, followed by the exercise test.
Trial: NCT01120275
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02673463
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg once daily
Trial: NCT02673463
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visually identical to spironolactone, once daily
Trial: NCT00961363
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02181348
Drug: placebo (edible oil)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01879371
Drug: Ibuprofen+caffeine FDC
RxNorm normalized name: caffeine / ergotamine / ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral dose
Trial: NCT01879371
Drug: Ibuprofen (Nurofen Immedia®)
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral dose
Trial: NCT01879371
Drug: Ibuprofen (Brufen®)
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral dose
Trial: NCT01367912
Drug: estradiol tablet
RxNorm normalized name: Estradiol Tablets
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: received 2 mg estradiol tablets orally two times daily beginning from the first day after hCG injection, in addition to vaginal progesterone gel